154 related articles for article (PubMed ID: 33035688)
1. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
2. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
Furukawa R; Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
[TBL] [Abstract][Full Text] [Related]
3. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
5. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
[TBL] [Abstract][Full Text] [Related]
6. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
7. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
Yamada Y; Harashima H
Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of A1555G and C1494T point mutations in the mitochondrial 12S rRNA gene by on/off switch.
Guo ZF; Guo WS; Xiao L; Gao GQ; Lan F; Lu XG; Li K; Liao DF
Appl Biochem Biotechnol; 2012 Jan; 166(1):234-42. PubMed ID: 22068689
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
[TBL] [Abstract][Full Text] [Related]
14. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
16. Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations.
Guan MX; Yan Q; Li X; Bykhovskaya Y; Gallo-Teran J; Hajek P; Umeda N; Zhao H; Garrido G; Mengesha E; Suzuki T; del Castillo I; Peters JL; Li R; Qian Y; Wang X; Ballana E; Shohat M; Lu J; Estivill X; Watanabe K; Fischel-Ghodsian N
Am J Hum Genet; 2006 Aug; 79(2):291-302. PubMed ID: 16826519
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
18. Packaging of the Coenzyme Q
Yamada Y; Burger L; Kawamura E; Harashima H
Biol Pharm Bull; 2017; 40(12):2183-2190. PubMed ID: 29199241
[TBL] [Abstract][Full Text] [Related]
19. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
[TBL] [Abstract][Full Text] [Related]
20. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
